| Naturally occurring off-switches for CRISPR-Cas9 A Pawluk, N Amrani, Y Zhang, B Garcia, Y Hidalgo-Reyes, J Lee, A Edraki, ... Cell 167 (7), 1829-1838. e9, 2016 | 421 | 2016 |
| A broad-spectrum inhibitor of CRISPR-Cas9 LB Harrington, KW Doxzen, E Ma, JJ Liu, GJ Knott, A Edraki, B Garcia, ... Cell 170 (6), 1224-1233. e15, 2017 | 272 | 2017 |
| A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing A Edraki, A Mir, R Ibraheim, I Gainetdinov, Y Yoon, CQ Song, Y Cao, ... Molecular cell 73 (4), 714-726. e4, 2019 | 229 | 2019 |
| Type II-C CRISPR-Cas9 biology, mechanism, and application A Mir, A Edraki, J Lee, EJ Sontheimer ACS chemical biology 13 (2), 357-365, 2018 | 149 | 2018 |
| NmeCas9 is an intrinsically high-fidelity genome-editing platform N Amrani, XD Gao, P Liu, A Edraki, A Mir, R Ibraheim, A Gupta, KE Sasaki, ... Genome Biology 19, 1-25, 2018 | 129 | 2018 |
| Potent Cas9 inhibition in bacterial and human cells by AcrIIC4 and AcrIIC5 anti-CRISPR proteins J Lee, A Mir, A Edraki, B Garcia, N Amrani, HE Lou, I Gainetdinov, ... MBio 9 (6), 10.1128/mbio. 02321-18, 2018 | 90 | 2018 |
| Structures of Neisseria meningitidis Cas9 complexes in catalytically poised and anti-CRISPR-inhibited states W Sun, J Yang, Z Cheng, N Amrani, C Liu, K Wang, R Ibraheim, A Edraki, ... Molecular cell 76 (6), 938-952. e5, 2019 | 82 | 2019 |
| 5′-Modifications improve potency and efficacy of DNA donors for precision genome editing KS Ghanta, Z Chen, A Mir, GA Dokshin, PM Krishnamurthy, Y Yoon, ... Elife 10, e72216, 2021 | 46 | 2021 |
| Anti-CRISPR AcrIIA5 potently inhibits all Cas9 homologs used for genome editing B Garcia, J Lee, A Edraki, Y Hidalgo-Reyes, S Erwood, A Mir, CN Trost, ... Cell reports 29 (7), 1739-1746. e5, 2019 | 43 | 2019 |
| CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro KE Meijboom, A Abdallah, NP Fordham, H Nagase, T Rodriguez, C Kraus, ... Nature communications 13 (1), 6286, 2022 | 34 | 2022 |
| Targeted CRISPR Delivery Platforms EJ Sontheimer, R Ibraheim, W Xue, A Mir, A Edraki, I Gainetdinov US Patent App. 16/186,352, 2022 | 1 | 2022 |
| One Anti-CRISPR to Rule Them All: Potent Inhibition of Cas9 Homologs Used for Genome Editing B Garcia, J Lee, A Edraki, Y Hidalgo-Reyes, S Erwood, A Mir, C Trost, ... Available at SSRN 3385124, 2019 | 1 | 2019 |
| Programmable dna base editing by nme2cas9-deaminase fusion proteins EJ Sontheimer, X Gao, A Mir, A Edraki, SA Wolfe, P Liu US Patent App. 17/285,440, 2022 | | 2022 |
| Edición programable de base de adn mediante proteínas de fusión nme2cas9-desaminasa A Edraki, EJ Sontheimer, X Gao, A Mir, SA Wolfe, P Liu | | 2021 |
| Programmable dna base editing by nme2cas9-deaminase fusion proteins EJ SONTHEIMER, X Gao, MIR Aamir, A Edraki, SA Wolfe, LIU Pengpeng | | 2021 |
| edição de base de dna programável pelas proteínas de fusão nme2cas9-desaminase EJ Sontheimer, X Gao, A Mir, A Edraki, SA Wolfe, P Liu | | 2021 |
| DNA editing programmed by deaminase-nme2cas9 chimeric proteins EJ Sontheimer, G Xin, A Mir, A Edraki, SA Wolfe, P Liu | | 2021 |
| CRISPR/Cas9-Mediated Excision of ALS/FTD-Causing Hexanucleotide Repeat Expansion in C9ORF72 Rescues Major Disease Mechanisms In Vivo and In Vitro KE Meijboom, A Abdallah, N Fordham, H Nagase, TF Gendron, ... MOLECULAR THERAPY 29 (4), 30-30, 2021 | | 2021 |
| Development of Cytosine and Adenine Base Editors with an Expanded Targeting Range P Liu, K Luk, K Ponnienselvan, XD Gao, A Edraki, EJ Sontheimer, ... MOLECULAR THERAPY 28 (4), 105-105, 2020 | | 2020 |
| Programmable dna base editing by nme2cas9-deaminase fusion proteins EJ Sontheimer, X Gao, MIR Aamir, A EDRAKI, SA Wolfe, LIU Pengpeng | | 2020 |
Erik SontheimerRNA Therapeutics Institute, UMass Medical SchoolVerified email at umassmed.edu
